MDxHealth expands prostate cancer test portfolio

© Reuters.

IRVINE, CA – MDxHealth SA (NASDAQ: MDXH), a precision diagnostic company, announced today the launch of a new genetic test for hereditary prostate cancer. This addition to the company’s portfolio allows for non-invasive testing using a saliva sample to provide insights into a patient’s risk of developing prostate cancer, as well as their potential disease progression and response to treatments.

The test aligns with National Comprehensive Cancer Network (NCCN) guidelines and is covered by Medicare and many commercial insurance plans for qualifying patients. Michael K. McGarrity, CEO of MDxHealth, stated, “The addition of this test to our menu reflects our commitment to delivering clinically actionable precision diagnostics to our urology customer base.”

Prostate cancer is a leading cause of cancer-related death among men, with an estimated 288,300 new cases and 34,700 deaths annually. Research suggests a significant genetic component in prostate cancer, with implications for ancestry.

MDxHealth’s new test is expected to contribute to the company’s revenue and growth in the second half of the year. The announcement comes as part of the company’s strategy to enhance its diagnostic offerings and provide molecular information to personalize patient diagnosis and treatment.

The company’s tests are based on proprietary genomic and epigenetic technologies and are designed to assist physicians in the diagnosis and prognosis of urologic cancers and diseases. The addition of the hereditary prostate cancer test is seen as a strategic move to strengthen MDxHealth’s position in the precision diagnostics market.

The information for this article is based on a press release statement from MDxHealth.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.